Report cover image

North America Human Microbiome Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

Publisher The Insight Partners
Published Sep 01, 2025
Length 129 Pages
SKU # TIP20577504

Description

The North American human microbiome market is projected to grow significantly, reaching approximately USD 2,811.82 million by 2031, up from USD 654.89 million in 2023, reflecting a compound annual growth rate (CAGR) of 20.0% from 2023 to 2031.

Executive Summary and Market Analysis

North America stands as the leading region for epigenetics and microbiome research, with the United States commanding the largest market share, followed by Canada. The growth of the human microbiome market in this region is driven by several factors, including extensive research initiatives, increased funding for biotechnology, heightened health awareness among consumers, and a growing demand for probiotics and prebiotics aimed at managing chronic diseases. Additionally, there is a strong emphasis on developing microbiome-based therapeutics, an increase in relevant conferences, and the presence of key local players, all of which are expected to enhance market growth and revenue generation.

Market Segmentation Analysis

The North American human microbiome market can be segmented by type, application, and disease type:

Type: The market is divided into products and software/services, with products holding a larger market share in 2023. The product segment is further categorized into probiotics and prebiotics.
Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics dominating the market share in 2023.
Disease Type: The market is classified into categories such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with GIT issues leading the market in 2023.

Market Outlook

Government initiatives and support programs play a crucial role in the growth of the human microbiome market. Substantial funding and grants are often allocated for microbiome research, which accelerates the development of new treatments, devices, and diagnostics. For example, the National Institutes of Health (NIH) has committed USD 115 million over five years to support the Human Microbiome Project, which aims to enhance understanding of human health and improve disease prevention, diagnosis, and treatment. Such funding fosters innovation and commercialization, particularly for startups and small-to-medium enterprises (SMEs) in the microbiome sector. Furthermore, the establishment of regulatory frameworks for microbiome-based products can streamline the introduction of new treatments, ensuring safety and efficacy, which in turn boosts consumer confidence and market acceptance.

Country Insights

The North American human microbiome market includes the United States, Canada, and Mexico, with the US holding the largest market share in 2023. The application of microbiome research is rapidly expanding within biotechnology, emerging as a vital therapeutic approach for various chronic diseases. This has led to increased private investment and advancements in environmental microbiome engineering. Over the past decade, the US has invested around USD 1 billion in human microbiome research, with approximately 20% of this funding directed towards the Human Microbiome Project (HMP). Launched in 2007, the HMP aims to create essential research resources for studying the human microbiome, resulting in significant contributions to microbiome research and therapy development.

Recent Developments

The demand for human microbiome therapeutics in the US is further fueled by product launches and regulatory approvals. For instance, in November 2022, Ferring Pharmaceuticals received FDA approval for REBYOTA, a first-in-class microbiota-based live biotherapeutic designed to prevent recurrent Clostridioides difficile infections in adults following antibiotic treatment.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are pursuing various strategies such as market expansion, product innovation, and mergers and acquisitions to enhance their offerings and increase market share.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America human microbiome market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the North America human microbiome market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America human microbiome market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

Table of Contents

129 Pages
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. North America Human Microbiome Market Landscape
4.1 Overview
4.2 PEST Analysis
5. North America Human Microbiome Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Significant Investments by Key Market Players
5.1.2 Government Initiatives
5.2 Market Restraints
5.2.1 Challenges During Production of Microbiome
5.3 Market Opportunities
5.3.1 Robust Investment in Research and Development
5.4 Future Trends
5.4.1 Emergence of Precision Medicine
5.5 Impact of Drivers and Restraints:
6. North America Human Microbiome Market – Analysis
6.1 North America Human Microbiome Market Revenue (US$ Million), 2021–2031
6.2 North America Human Microbiome Market Forecast Analysis
7. North America Human Microbiome Market Analysis – by Type
7.1 Product
7.1.1 Overview
7.1.2 Product: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
7.2 Software and Services
7.2.1 Overview
7.2.2 Software and Services: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
8. North America Human Microbiome Market Analysis – by Application
8.1 Therapeutics
8.1.1 Overview
8.1.2 Therapeutics: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.2 Diagnostics
8.2.1 Overview
8.2.2 Diagnostics: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.3 Research
8.3.1 Overview
8.3.2 Research: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9. North America Human Microbiome Market Analysis – by Disease Type
9.1 Obesity
9.1.1 Overview
9.1.2 Obesity: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.2 Diabetes
9.2.1 Overview
9.2.2 Diabetes: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.3 Autoimmune Disorder
9.3.1 Overview
9.3.2 Autoimmune Disorder: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.4 Cancer
9.4.1 Overview
9.4.2 Cancer: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.5 GIT
9.5.1 Overview
9.5.2 GIT: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
10. North America Human Microbiome Market – Country Analysis
10.1 North America
10.1.1 North America Human Microbiome Market – Revenue and Forecast Analysis – by Country
10.1.1.1 North America Human Microbiome Market – Revenue and Forecast Analysis – by Country
10.1.1.2 United States: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.1.1.2.1 United States: North America Human Microbiome Market Share – by Type
10.1.1.2.2 United States: North America Human Microbiome Market Share – by Product
10.1.1.2.3 United States: North America Human Microbiome Market Share – by Application
10.1.1.2.4 United States: North America Human Microbiome Market Share – by Disease Type
10.1.1.3 Canada: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.1.1.3.1 Canada: North America Human Microbiome Market Share – by Type
10.1.1.3.2 Canada: North America Human Microbiome Market Share – by Product
10.1.1.3.3 Canada: North America Human Microbiome Market Share – by Application
10.1.1.3.4 Canada: North America Human Microbiome Market Share – by Disease Type
10.1.1.4 Mexico: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.1.1.4.1 Mexico: North America Human Microbiome Market Share – by Type
10.1.1.4.2 Mexico: North America Human Microbiome Market Share – by Product
10.1.1.4.3 Mexico: North America Human Microbiome Market Share – by Application
10.1.1.4.4 Mexico: North America Human Microbiome Market Share – by Disease Type
11. Competitive Landscape
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Human Microbiome Market
12.3 Organic Growth Strategies
12.3.1 Overview
12.4 Inorganic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Ferring Holdings SA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 AOBiome Therapeutics Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Finch Therapeutics Group Inc
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Financial Overview
13.4.4 SWOT Analysis
13.4.5 Key Developments
13.5 Seres Therapeutics Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Merck & Co Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Yakult Honsha Co., Ltd.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Rebiotix, Inc.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 IFF Nutrition & Biosciences
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Synthetic Biologics, Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About Us
14.2 List of Abbreviations
List of Tables
Table 1. North America Human Microbiome Market Segmentation
Table 2. North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Table 3. North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Type
Table 4. North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Application
Table 5. North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Disease Type
Table 6. North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 7. United States: North America Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 8. United States: North America Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 9. United States: North America Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 10. United States: North America Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 11. Canada: North America Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 12. Canada: North America Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 13. Canada: North America Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 14. Canada: North America Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 15. Mexico: North America Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 16. Mexico: North America Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 17. Mexico: North America Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 18. Mexico: North America Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 19. Recent Organic Growth Strategies in the Human Microbiome Market
Table 20. Recent Inorganic Growth Strategies in the Human Microbiome Market
Table 21. List of Abbreviations
List of Figures
Figure 1. North America Human Microbiome Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. North America Human Microbiome Market – Key Market Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. North America Human Microbiome Market Revenue (US$ Million), 2021–2031
Figure 6. North America Human Microbiome Market Share (%) – by Type (2023 and 2031)
Figure 7. Product: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 8. Software and Services: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 9. North America Human Microbiome Market Share (%) – by Application (2023 and 2031)
Figure 10. Therapeutics: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 11. Diagnostics: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 12. Research: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 13. North America Human Microbiome Market Share (%) – by Disease Type (2023 and 2031)
Figure 14. Obesity: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 15. Diabetes: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 16. Autoimmune Disorder: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 17. Cancer: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 18. GIT: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 19. Others: North America Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 20. North America Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 21. United States: North America Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 22. Canada: North America Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 23. Mexico: North America Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 24. Heat Map Analysis by Key Players
Figure 25. Company Positioning and Concentration
Figure 26. Growth Strategies in the Human Microbiome Market

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us